Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 GlobeNewswire August 08, 2025 NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, […]

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility GlobeNewswire August 08, 2025 FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original study

ECARX Powers Launch of Geely Galaxy A7, Further Expanding Market Deployment of Antora and Cloudpeak Solutions

ECARX Powers Launch of Geely Galaxy A7, Further Expanding Market Deployment of Antora and Cloudpeak Solutions GlobeNewswire August 08, 2025 SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology provider, today announced that its AI Enhanced Antora(R) 1000 computing platform and Cloudpeak(R) cross-domain software

Gencor Releases Third Quarter Fiscal 2025 Results

Gencor Releases Third Quarter Fiscal 2025 Results GlobeNewswire August 08, 2025 ORLANDO, Fla., Aug. 08, 2025 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue increased 5.6% for the quarter ended June 30, 2025 to $26,986,000 from $25,551,000 for the quarter ended June 30, 2024. Revenue from

Flutter Entertainment plc announces launch of fourth tranche of share repurchase program

(NYSE:FLUT),(LSE:FLTR),(OTC US:FLUT),(Other OTC:FLUT), NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment plc (“Flutter”) (NYSE:FLUT; LSE:FLTR), the world's leading online sports betting and iGaming operator, announces that it has entered into non-discretionary arrangements with Davy Securities UC to repurchase ordinary shares on Flutter's behalf for an aggregate maximum consideration of up to $245 million

UNDER ARMOUR REPORTS FIRST QUARTER FISCAL 2026 RESULTS; PROVIDES SECOND QUARTER FISCAL 2026 OUTLOOK

Under Armour, Inc. (NYSE: UAA, UA) announced its unaudited financial results for its first quarter of fiscal 2026, whichended on June 30, 2025. The company reports its financial performance in accordance with generally accepted accounting principles in the United States (“GAAP”). This press release includes references to “currency neutral” and “adjusted” amounts, which are non-GAAP

Second Life EV Battery Market worth 330-350 GWH by 2030 | MarketsandMarkets™

The second life EV battery market is estimated at ~25-30 GWH in 2025 and is projected to reach ~330-350 GWH in 2030 at a CAGR of ~65% during the forecast period, according to a new report by MarketsandMarkets.The growing adoption of electric vehicles (EVs) is expected to fuel a multibillion-dollar market for second-life batteries by

Flutter Entertainment plc announces launch of fourth tranche of share repurchase program

Flutter Entertainment plc announces launch of fourth tranche of share repurchase program GlobeNewswire August 08, 2025 NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) — Flutter Entertainment plc (“Flutter”) (NYSE:FLUT; LSE:FLTR), the world's leading online sports betting and iGaming operator, announces that it has entered into non-discretionary arrangements with Davy Securities UC to repurchase ordinary shares

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

(NasdaqGM:ANIP), Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis Total Rare Disease quarterly net revenues of $104.0 million, which includes: Purified Cortrophin(R) Gel net revenues of $81.6 million, an increase of 66.0% year-over-year, and ILUVIEN(R) and YUTIQ(R) net revenues of

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance GlobeNewswire August 08, 2025 Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis Total Rare Disease quarterly net revenues of $104.0 million, which includes: Purified Cortrophin(R) Gel net

Scroll to Top